Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 37 recruiting now later-stage tilt #66 of 28,707 conditions

Bipolar Disorder: later-stage trial registry

37 of 163 indexed Bipolar Disorder trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #66 of 28,707 conditions by registered trial count.

163 US clinical trials · 37 currently recruiting · #66 of 28,707 conditions by registered trial count

Bipolar Disorder: 163 US clinical trials tracked, 37 recruiting.

Bipolar Disorder is the subject of 163 registered US clinical trials on ClinicalTrials.gov, 37 of them currently open to new participants. 45 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 11 of these trials.

Enrollment posture brief

Registry condition bipolar-disorder

OPEN 37 | RECR 23% | LATE 45 | EARLY 15 | RANK #66 | SPON 11

Nearest open-share peer: Hypogonadism (23% recruiting · 22 trials)

Epilepsy47.6%Gastric Cancer45.3%Neoplasms31.3%Parkinson's Disease26.1%Bipolar Disorder (this)23%
Open-enrollment share among volume-matched conditions near Bipolar Disorder

Bipolar Disorder lists 37 open slots (23% of 163 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Bipolar Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Bipolar Disorder is recruiting below its size-band peers.

    37 of 163 indexed trials (22.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Bipolar Disorder trials is spread across many organizations.

    Massachusetts General Hospital accounts for 11 of 163 trials (6.7%). 73 distinct sponsors appear on at least one study for this condition label.

  3. Typical Bipolar Disorder enrolment sits around 75 participants.

    Median target enrolment is 75 among the 163 trials that report a genuine target (sentinel values excluded). 92 of those (56.4%) plan for fewer than 100 participants.

  4. Bipolar Disorder research is mostly interventional.

    133 interventional and 30 observational studies make up this index (81.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 212Phase 323Phase 422

Open and recent trials

163 total, page 2 of 4

COMPLETED Phase 3 676 participants

Seroquel in Bipolar Depression Versus SSRI

AstraZeneca

NCT00119652

COMPLETED Phase 3 488 participants

Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression

Forest Laboratories

NCT02670551

COMPLETED Phase 3 434 participants

Study Evaluating Bifeprunox in Bipolar Depression

Wyeth is now a wholly owned subsidiary of Pfizer

NCT00134459

COMPLETED NA 384 participants

Adapting the Bipolar Care Model for Chronic Care Management in Community-based Health Care Sites

University of Michigan

NCT00747201

COMPLETED Phase 3 380 participants

Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder

BioXcel Therapeutics

NCT04276883

COMPLETED Phase 3 379 participants

Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents

Washington University School of Medicine

NCT00057681

COMPLETED Phase 3 343 participants

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

Novartis Pharmaceuticals

NCT00107926

COMPLETED Phase 4 340 participants

Optimizing Electroconvulsive Therapy for Depression

New York State Psychiatric Institute

NCT00045916

COMPLETED Phase 3 301 participants

Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients

GlaxoSmithKline

NCT00723450

COMPLETED 300 participants

A Study of Pregnant and Postpartum Women With and Without Mood Disorders

Johns Hopkins University

NCT03615794

COMPLETED NA 292 participants

Early Detection and Intervention for the Prevention of Psychosis

MaineHealth

NCT00531518

COMPLETED NA 291 participants

Implementation Trial of Evidence Based Practices for Mood Disorders

University of Arkansas

NCT02150577

COMPLETED NA 240 participants

The Appeal and Impact of E-cigarettes in Smokers With SMI

Dartmouth-Hitchcock Medical Center

NCT03050853

COMPLETED Phase 4 224 participants

Treatment of Bipolar Mania in Older Adults

Weill Medical College of Cornell University

NCT00254488

COMPLETED 224 participants

A Study of the Relationship of Psychosocial Function With Mood Symptoms in Offspring of Parents With Bipolar Disorder

Janssen Research & Development

NCT03017781

COMPLETED Phase 3 220 participants

Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.

Hadassah Medical Organization

NCT00158990

COMPLETED NA 205 participants

LiveWell: A Mobile Intervention for Bipolar Disorder

Northwestern University

NCT03088462

COMPLETED Phase 4 181 participants

Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder

Novartis

NCT00139594

COMPLETED NA 180 participants

Examination of Glutamate and mGluR5 in Psychiatric Disorders

Yale University

NCT02727972

COMPLETED NA 174 participants

Comparing Mobile Health (mHealth) and Clinic-Based Self-Management Interventions for Serious Mental Illness

Dartmouth-Hitchcock Medical Center

NCT02421965

COMPLETED Phase 2 168 participants

Supported Employment: Motivational Enhancement for Entry and Outcome

VA Office of Research and Development

NCT01041976

COMPLETED NA 168 participants

Virtual Reality Job Interview Training in Severe Mental Illness

University of Michigan

NCT03049813

COMPLETED Phase 1 152 participants

Valproate Efficacy in Cocaine-Bipolar Comorbidity

University of Miami

NCT00240110

COMPLETED 150 participants

The Evaluation and Follow-up of Patients With Bipolar Disorder

National Institute of Mental Health (NIMH)

NCT00001652

COMPLETED Phase 3 150 participants

An Outpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder in Children and Adolescents

Abbott

NCT00067262

COMPLETED 139 participants

The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders

NYU Langone Health

NCT03166098

COMPLETED NA 123 participants

Contingency Management of Alcohol Abuse in the Severely Mentally ILL

University of Washington

NCT01567943

COMPLETED Phase 3 120 participants

Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)

University Hospitals Cleveland Medical Center

NCT00671853

COMPLETED NA 120 participants

Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI

Dartmouth-Hitchcock Medical Center

NCT02334280

COMPLETED 118 participants

Bipolar Disorder in Pregnancy and the Postpartum Period: Predictors of Morbidity

Massachusetts General Hospital

NCT00580268

COMPLETED Phase 3 118 participants

Self-Management Addressing Heart Disease Risk Trial

US Department of Veterans Affairs

NCT00499096

COMPLETED Phase 4 115 participants

Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence

University of Texas Southwestern Medical Center

NCT00223249

COMPLETED NA 108 participants

Family Intervention for Mental Illness and Substance Abuse

Dartmouth-Hitchcock Medical Center

NCT00043693

COMPLETED 107 participants

Brain Imaging in Depression

National Institute of Mental Health (NIMH)

NCT00050700

COMPLETED Phase 4 103 participants

Targeting Cognition in Bipolar Disorder With Pramipexole

Brigham and Women's Hospital

NCT02397837

COMPLETED Phase 3 102 participants

Acute Treatment of Bipolar II Depression

Stanford University

NCT00074776

COMPLETED 102 participants

Bipolar Disorder in Epilepsy

Northwell Health

NCT00365482

COMPLETED NA 90 participants

Development of a Personalized Real-time Intervention for Bipolar Disorder

University of California, San Diego

NCT01670123

COMPLETED NA 88 participants

Pilot Trial of Peer Support for Bipolar Disorder

Kaiser Permanente

NCT02404246

COMPLETED NA 87 participants

Mobile Self-Tracking of Mental Health

VA Office of Research and Development

NCT05023252

COMPLETED 80 participants

Neuroimaging Epigenetics of Prospective Postpartum Depression Biomarkers

Johns Hopkins University

NCT03638687

COMPLETED NA 78 participants

Development of a Mobile Heath Augmented Brief Suicide Prevention Intervention for People With SMI

University of California, San Diego

NCT03198364

COMPLETED Phase 3 75 participants

Aripiprazole for Bipolar Disorder and Alcohol Use Disorder

University of Texas Southwestern Medical Center

NCT02918370

COMPLETED Phase 3 75 participants

Treatment of Mania Symptoms With Drug Therapy

Palo Alto Veterans Institute for Research

NCT00183443

COMPLETED Phase 4 75 participants

Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania

University of Cincinnati

NCT00393978

COMPLETED NA 65 participants

Reducing Suicide Risk in Adolescents and Young Adults Via a Psychobehavioral Intervention to Regularize Daily Rhythms

Yale University

NCT05317481

COMPLETED NA 65 participants

Omega-3 Fatty Acids in Children and Adolescents With Bipolar Disorder

University of Rochester

NCT00252486

COMPLETED NA 62 participants

Uridine Adolescent Bipolar Depression Randomized Controlled Trial

University of Utah

NCT01805440

COMPLETED Phase 3 60 participants

Study of Aripiprazole (Abilify) in Children With Symptoms of Mania

University Hospitals Cleveland Medical Center

NCT00194077

COMPLETED Phase 4 60 participants

Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study

University of Pittsburgh

NCT00177567

← Previous Page 2 of 4 Next →

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 12
Phase 3 23
Phase 4 22

Named interventions

Most-linked intervention names on Bipolar Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
19 trials
Lithium Drug
9 trials
Quetiapine Drug
4 trials
Aripiprazole Drug
3 trials
Valproate Drug
3 trials
Lamotrigine Drug
3 trials
Placebo Other
3 trials
paroxetine Drug
2 trials

US sites by state

Facility locations filed on Bipolar Disorder trials. A trial with sites in several states counts in each.

California 35 trials
Massachusetts 32 trials
Texas 26 trials
New York 24 trials
Ohio 23 trials
Maryland 18 trials
Florida 18 trials
Pennsylvania 17 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Bipolar Disorder page

163 registered trials, 37 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bipolar Disorder condition card totals 163 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.